Brokerages Set Arvinas, Inc. (NASDAQ:ARVN) PT at $13.88

Arvinas, Inc. (NASDAQ:ARVN) has been given a consensus recommendation of “Hold” by the nineteen analysts that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $13.8824.

A number of equities research analysts have issued reports on ARVN shares. Truist Financial set a $10.00 price objective on Arvinas in a research report on Wednesday, March 18th. Piper Sandler reissued an “overweight” rating and set a $20.00 target price (up from $16.00) on shares of Arvinas in a research report on Wednesday, February 25th. Wedbush increased their price target on Arvinas from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Tuesday, February 24th. Wall Street Zen downgraded Arvinas from a “hold” rating to a “sell” rating in a research report on Monday, March 2nd. Finally, Barclays lifted their price objective on shares of Arvinas from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th.

Insider Transactions at Arvinas

In other news, Director John G. Houston sold 35,297 shares of the firm’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $13.21, for a total value of $466,273.37. Following the completion of the sale, the director owned 1,122,183 shares in the company, valued at approximately $14,824,037.43. This trade represents a 3.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Briggs Morrison purchased 20,000 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The shares were purchased at an average cost of $13.40 per share, with a total value of $268,000.00. Following the completion of the purchase, the director owned 96,021 shares in the company, valued at $1,286,681.40. This trade represents a 26.31% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have sold 63,864 shares of company stock worth $802,443. 4.73% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ARVN. Hsbc Holdings PLC grew its stake in shares of Arvinas by 18.8% during the fourth quarter. Hsbc Holdings PLC now owns 73,779 shares of the company’s stock valued at $876,000 after buying an additional 11,672 shares during the last quarter. Corient Private Wealth LLC bought a new stake in shares of Arvinas during the 4th quarter worth approximately $127,000. Invesco Ltd. boosted its holdings in Arvinas by 26.9% during the 4th quarter. Invesco Ltd. now owns 302,100 shares of the company’s stock valued at $3,583,000 after acquiring an additional 64,044 shares during the period. State of Tennessee Department of Treasury purchased a new position in Arvinas during the 4th quarter valued at $323,000. Finally, Ikarian Capital LLC grew its position in Arvinas by 58.3% in the 4th quarter. Ikarian Capital LLC now owns 358,257 shares of the company’s stock valued at $4,249,000 after acquiring an additional 132,000 shares during the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Stock Down 7.1%

Arvinas stock opened at $10.10 on Friday. The company’s 50-day moving average price is $12.53 and its 200-day moving average price is $11.27. The company has a market cap of $646.00 million, a PE ratio of -7.89 and a beta of 1.87. Arvinas has a twelve month low of $5.90 and a twelve month high of $14.51.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.55). Arvinas had a negative net margin of 30.77% and a negative return on equity of 14.25%. The business had revenue of $9.50 million during the quarter, compared to the consensus estimate of $37.26 million. During the same period in the previous year, the business posted ($0.63) EPS. The firm’s revenue was down 84.0% on a year-over-year basis. As a group, sell-side analysts expect that Arvinas will post -3.81 earnings per share for the current fiscal year.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.